To test this hypothesis, we first analyzed the relationship between the expression level of CRABP2 and the sensitivity of patients to chemotherapy in 128 ovarian cancer patients, and the results showed that the tumor tissues that were not sensitive to chemotherapy had a high level of CRABP2 expression (Fig. 2A). The gene discussed is CRABP2; the disease is ovarian cancer.